Applicability of the IMPROVE-IT Trial to Current Patients With Acute Coronary Syndrome: An NCDR Research to Practice Project

Thomas M Maddox; Fengming Tang; John R Downs; Frederick A Masoudi; Salim S Virani; Stacie L Daugherty; John S Rumsfeld

doi:10.1001/jamainternmed.2017.0754

Applicability of the IMPROVE-IT Trial to Current Patients With Acute Coronary Syndrome: An NCDR Research to Practice Project

JAMA Intern Med. 2017 Jun 1;177(6):887-889. doi: 10.1001/jamainternmed.2017.0754.

Authors

Thomas M Maddox¹, Fengming Tang², John R Downs³, Frederick A Masoudi⁴, Salim S Virani⁵, Stacie L Daugherty⁴, John S Rumsfeld⁶

Affiliations

¹ VA Eastern Colorado Health Care System, Denver2University of Colorado School of Medicine, Denver3Colorado Cardiovascular Outcomes Research (CCOR) Consortium, Denver.
² Mid-America Heart Institute, Kansas City, Missouri.
³ University of Texas Health Science Center San Antonio, San Antonio.
⁴ University of Colorado School of Medicine, Denver3Colorado Cardiovascular Outcomes Research (CCOR) Consortium, Denver.
⁵ Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, Texas.
⁶ University of Colorado School of Medicine, Denver3Colorado Cardiovascular Outcomes Research (CCOR) Consortium, Denver7American College of Cardiology, Washington DC.

Abstract

This study examines the proportion of current patients with acute coronary syndrome in the American College of Cardiology practice innovation and clinical excellence ambulatory cardiology practice registry that would have qualified for the IMPROVE-IT trial, and how their characteristics compared with trial participants.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Acute Coronary Syndrome / drug therapy*
Aged
Aged, 80 and over
Anticholesteremic Agents / therapeutic use*
Clinical Trials as Topic
Drug Therapy, Combination
Ezetimibe / therapeutic use*
Female
Humans
Male
Middle Aged
Registries*
Simvastatin / therapeutic use*

Substances

Anticholesteremic Agents
Simvastatin
Ezetimibe